NEW YORK (GenomeWeb News) — Ciphergen said in a US Securities and Exchange Commission filing last week that its current cash balances “may not be sufficient to fund planned expenditures."
 
According to the company, "This raises substantial doubt about our ability to continue as a going concern."
 
The disclosure came a few days after Ciphergen said in an earlier SEC filing that first-quarter revenue ran dry as R&D spending dropped 36 percent and losses widened 11 percent.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.